Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
(Thomson Reuters ONE) -
Selective JAK1 inhibitor in Phase II clinical development for rheumatoid
arthritis
Abbott to Retain Exclusive Global Commercial Rights with Galapagos co-promotion
in Benelux Countries
Galapagos to Receive Upfront Payment of $150 Million, with the Potential for
Significant Milestone Payments
Galapagos to host webcast presentation today at 4 pm CET/ 10am Eastern US/ 7 am
Pacific
Abbott Park, Illinois and Mechelen, Belgium; 29 February 2012 - Abbott (NYSE:
ABT) and Galapagos (Euronext: GLPG) announced today that they have entered into
a global collaboration to develop and commercialize an oral, next-generation
JAK1 inhibitor in Phase II development with the potential to treat multiple
autoimmune diseases.
GLPG0634 is a highly selective JAK1 inhibitor that Galapagos is developing for
the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. The
Janus kinases (JAK) are a family of enzymes that play a key role in the
signaling mechanism used by a number of cytokines that are involved in
autoimmune diseases. In previously reported results from a 4-week Phase IIa
study, GLPG0634 demonstrated efficacy measures among the best reported in RA.
All patients completed the study, and few experienced any side effects. No
anemia, change in blood pressure or lipids were observed. An additional Phase
IIa dose-range finding study with GLPG0634 is expected to begin shortly.
"The addition of this novel, oral compound offers patients the potential for
advanced treatment options and an improved patient experience to address RA and
other autoimmune diseases," said John Leonard, M.D., senior vice president,
global research and development, Abbott. "Abbott's expertise in immunology,
combined with a robust portfolio of investigational treatments represents
promising innovation across several areas of medical need."
"This collaboration with Abbott, the global leader in autoimmune diseases, is a
great recognition of the value of GLPG0634. We view Abbott to be the best
partner possible to deliver a complete clinical program and a powerful market
introduction. We are excited to continue the phase II trials and expect to
deliver to Abbott a complete Phase II package in 2014," said Onno van de Stolpe,
chief executive officer, Galapagos. "With GLPG0634 we have proven that we can
deliver from target to clinical Proof of Concept, and we aim to do the same on
many novel target programs in our pipeline. This collaboration is
transformational for Galapagos, providing the means to progress these innovative
products into the clinic."
Under the terms of the agreement, Abbott will make an initial upfront payment of
$150 million for rights related to the global collaboration. Upon successful
completion of the RA Phase II studies, Abbott will license the program for a
one-time fee of $200 million if the studies meet certain pre-agreed criteria.
Abbott will assume sole responsibility for Phase III clinical development and
global manufacturing. Pending achievement of certain developmental, regulatory,
commercial and sales-based milestones, Galapagos would be eligible to receive
additional milestone payments from Abbott, potentially amounting to $1.0
billion, in addition to tiered double-digit royalties on net sales upon
commercialization. Galapagos retains co-promotion rights in Belgium, the
Netherlands and Luxembourg.
Webcast presentation
Galapagos will hold an audio webcast presentation for journalists, analysts, and
investors today at 4 pm CET/10 am Eastern US/7 am Pacific US, viewable
atwww.glpg.com.
Call numbers:
Belgium 0800 50747
Netherlands 0800 265 8528
US 1-877-941-6009
Other countries +32 2290 1608 or +31 20 794 8504
Galapagos Forward-Looking Statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing GLPG0634
through Phase II and has one of the largest pipelines in biotech, with four
programs in development and over 50 discovery programs. The Galapagos Group has
about 800 employees and operates facilities in six countries, with global
headquarters in Mechelen, Belgium. More info at: www.glpg.com
Abbott Forward-Looking Statements
Some statements in this news release may be forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995. Abbott
cautions that these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially from those
indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's
operations are discussed in Item 1A, "Risk Factors," to our Annual Report on
Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011,
and are incorporated by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent
events or developments.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the
discovery, development, manufacture and marketing of pharmaceuticals and medical
products, including nutritionals, devices and diagnostics. The company employs
approximately 91,000 people and markets its products in more than 130 countries.
More information:
Abbott:
Media: Adelle Infante, +1-847-224-0359
Investors: Larry Peepo, +1-847-935-6722
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir(at)glpg.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1589669]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Dalradian Closes Norwegian AcquisitionDatum: 29.02.2012 - 07:32 Uhr
Sprache: Deutsch
News-ID 119773
Anzahl Zeichen: 8441
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 281 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
